XM does not provide services to residents of the United States of America.
C
C

Clorox

News

U.S. ANI Pharmaceuticals, Deere & Co, Zoetis

U.S. RESEARCH ROUNDUP-ANI Pharmaceuticals, Deere & Co, Zoetis Oct 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ANI Pharmaceuticals, Deere & Co and Zoetis, on Friday. HIGHLIGHTS * ANI Pharmaceuticals Inc ANIP.O : Piper Sandler initiates coverage with overweight rating * Deere & Co DE.N : JP Morgan raises target price to $420 from $360 * Northrop Grumman NOC.N : Citigroup raises target price to $587 from $521 * S
A
C
G
H
I
A
C
F
A
C
A
A
C
C
C
E

U.S. STOCKS Dine Brands, Pinterest, Nike

BUZZ-U.S. STOCKS ON THE MOVE-Dine Brands, Pinterest, Nike Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes took a beating on Tuesday as reports of escalating tensions in the Middle East made investors sell riskier assets, with the benchmark S&P 500 hitting its lowest in over a week.
A
A
C
L
N
P
S
L
U
U
L
A
C
J
M

U.S. STOCKS Paychex, Dine Brands, Pinterest

BUZZ-U.S. STOCKS ON THE MOVE-Paychex, Dine Brands, Pinterest Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slid on Tuesday as investors turned risk-averse following reports of geopolitical tensions escalating in the Middle East, while also assessing data that pointed to a stable labor market.
C
P
S
L
C
U
U
L
A
C
M

U.S. STOCKS Sagimet, Datadog, Clorox

BUZZ-U.S. STOCKS ON THE MOVE-Sagimet, Datadog, Clorox Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures were mixed on Tuesday ahead of the first of multiple labor market reports this week, a day after Federal Reserve Chair Jerome Powell pushed back against market expectations for outsized interest rate cuts.
B
G
S
C
U
I
A
C
M

Clorox gains as Jefferies upgrades to 'buy', raises PT

BUZZ-Clorox gains as Jefferies upgrades to 'buy', raises PT ** Shares of bleach maker Clorox CLX.N up 1.3% at $165.09 premarket ** Jefferies lifts rating on stock to "buy" from "hold" ** Raises PT from $174 to a Street high of $187, a 14.8% upside to last close ** "... we expect Clorox to return to its past, a company delivering peer-leading economic profit growth and return on capital," Jefferies analyst Kaumil Gajrawala writes ** On track to fully restore U.S.
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.